Active Biotech's rights issue of approximately SEK 225 million oversubscribed
(Thomson Reuters ONE) -
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO
THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA
OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS
PRESS RELEASE WOULD BE UNLAWFUL.
Following the end of the subscription period, the results of Active Biotech's
rights issue show that 14,736,623 shares, corresponding to approximately 98.3
percent of the shares offered, were subscribed for with subscription rights. In
addition thereto 3,857,742 shares, corresponding to approximately 26 percent of
the shares offered, were subscribed for without subscription rights. The rights
issue was thereby oversubscribed with approximately 24 percent.
The shares that were subscribed for without subscription rights have been
allotted to the subscribers in accordance with the principles outlined in the
prospectus. Notification regarding such allocation is only sent to those who
have been allotted shares. Through the rights issue, Active Biotech will receive
proceeds amounting to approximately SEK 225 million, before issue costs.
Furthermore, Active Biotech's share capital increases through the rights issue
by approximately SEK 56,482,529.18 to approximately SEK 338,895,182.64 and the
total number of shares increases by 14,984,716 to 89,908,298 shares.
The new shares are expected to be registered with the Swedish Companies
Registration Office on or about January 16, 2015 and trading in the new shares
on Nasdaq Stockholm is expected to commence on or about January 27, 2015.
For further information, please contact:
Tomas Leanderson, CEO
Tel: +46 (0)46 19 20 95
E-mail: tomas.leanderson(at)activebiotech.com
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam(at)activebiotech.com
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company
with focus on neurodegenerative diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, and
tasquinimod, an oral immunomodulatory, anti-metastatic substance for the
treatment of prostate cancer. The objective of the preclinical ISI project is to
produce new, patentable chemical compounds for treatment of diseases in the
company's focus areas. Please visit www.activebiotech.com for more information.
Active Biotech is required to publish the information contained in this press
release in accordance with the Swedish Securities Market Act. This information
was provided to the media for publication at 3.30 pm CET on December 29, 2014.
Important information
This press release is not an offer to subscribe for shares in Active Biotech. A
prospectus relating to the rights issue referred to in this press release has
been made public prior to the commencement of the subscription period. This
press release is not a prospectus and investors should not subscribe for or
purchase any securities, except on the basis of information provided in the
prospectus.
This press release may not be made public, released or distributed, directly or
indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada,
Singapore, South Africa or New Zealand or in any other jurisdiction in which the
distribution of this press release would be unlawful. Further, this press
release does not constitute an offer to sell new shares, paid subscribed for
shares ("BTA") or subscription rights to any person in any jurisdiction in which
it is unlawful to make such offer to such person or where such action would
require additional prospectuses, registration or other measures other than those
pursuant to Swedish law. The prospectus, application form and other documents
associated with the rights issue may not be distributed in or to any country
where such distribution or the rights issue would require such measures set
forth in the preceding sentence or be in violation of the regulations of such
country.
The new shares, BTAs and subscription rights have not been recommended by a
United States federal or state securities commission or regulatory authority. No
new shares, BTAs, subscription rights or other securities issued by Active
Biotech have been or will be registered under the U.S. Securities Act of 1933,
or under the securities legislation in any state of the United States or any
province in Canada. Accordingly, no new shares, BTAs, subscription rights or
other securities issued by Active Biotech may be transferred or offered for sale
in the United States or Canada, other than in such exceptional cases that do not
require registration. The securities issued in the rights issue will not be
offered to the public in the United States.
Active Biotech has not authorized any offer of securities to the public in any
country in the European Economic Area ("EEA") other than Sweden. In other member
states in the EEA which have implemented the Directive 2003/71/EC (the
"Prospectus Directive") (each, a "Relevant Member State"), no action has been
undertaken and will not be undertaken to make an offer of securities to the
public requiring publication of a prospectus in any Relevant Member State. As a
result, the securities may only be offered in Relevant Member States to (a) any
legal entity which is a qualified investor as defined in the Prospectus
Directive; or (b) any person falling within Article 3(2) of the Prospectus
Directive.
The rights issue is only directed at (i) persons who are outside the United
Kingdom or (ii) persons who have professional experience in matters relating to
investments falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the "Order") and (iii) high net worth
entities, and other persons to whom it may lawfully be communicated, falling
within Article 49(2) of the Order (all such persons together being referred to
as "relevant persons"). The securities issued in the rights issue will only be
available to and will only be engaged with, relevant persons. Any person who is
not a relevant person should not act or rely on this document or any of its
contents.
Active Biotech's rights issue of approximately SEK 225 million oversub:
http://hugin.info/1002/R/1883710/665437.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via GlobeNewswire
[HUG#1883710]
Unternehmensinformation / Kurzprofil:
Datum: 29.12.2014 - 15:30 Uhr
Sprache: Deutsch
News-ID 361663
Anzahl Zeichen: 7692
contact information:
Town:
LUND
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 495 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech's rights issue of approximately SEK 225 million oversubscribed"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
